E!114520-ACTION-Redoxis AB
| Reference number | |
| Coordinator | Redoxis AB |
| Funding from Vinnova | SEK 2 744 258 |
| Project duration | October 2020 - November 2024 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The objective was to develop the next generation of GnRH analogues to treat autoinflammatory diseases, with a strong anti-inflammatory effect and few side effects. 8 drug candidates have been evaluated in the model for collagen-induced arthritis in mice. Several drug candidates showed promising signs of efficacy with reduced disease and with a dose-response pattern. The effect on hormone levels was significantly less than marketed GnRH analogues, i.e. less side effects. Toxicity studies have identified the maximum tolerable dose. The goals of the program were largely fulfilled.
Expected long term effects
Several drug candidates showed promising signs of efficacy with reduced disease and with a dose-response pattern when evaluated in the collagen-induced arthritis mouse model. The effect on the degree of disease is promising and shows continued development potential for the drug candidates. Several of the candidates also have a favorable safety profile with little or no effect on measured hormone levels.
Approach and implementation
The plan was ambitious and did not take sufficient account of possible delays and other obstacles that may arise along the way. Good collaboration within the project has identified problems and found solutions going forward. After the program has been extended in time, the project has been implemented and the objectives have largely been achieved.